Indivior (NASDAQ:INDV – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Analyst Recommendations
This is a summary of current recommendations for Indivior and Korro Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indivior | 0 | 1 | 5 | 1 | 3.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Indivior currently has a consensus price target of $39.33, indicating a potential upside of 2.22%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 43.96%. Given Korro Bio’s higher possible upside, analysts clearly believe Korro Bio is more favorable than Indivior.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Indivior | 19.44% | -219.26% | 29.40% |
| Korro Bio | -1,834.48% | -117.86% | -71.04% |
Risk and Volatility
Indivior has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500.
Institutional & Insider Ownership
60.3% of Indivior shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Indivior and Korro Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indivior | $1.24 billion | 3.79 | $210.00 million | $1.95 | 19.73 |
| Korro Bio | $6.39 million | 26.20 | -$117.26 million | ($11.67) | -0.99 |
Indivior has higher revenue and earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Summary
Indivior beats Korro Bio on 8 of the 15 factors compared between the two stocks.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
